CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Difficult bup-nx inductions were not associated with participants’ primary PO. Severity of withdrawal, measured with the COWS, was an important variable, reminding clinicians that bup-nx should not be commenced prior to evidence of moderate opioid withdrawal. These findings add to the evidence that with careful procedures, bup-nx can used with few difficulties in PO-dependent patients. (Am J Addict 2013;XX:000-000).
PMID: 24112096 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)

Abstract: Buprenorphine (BPN) medication for opioid maintenance treatment in Finland consists predominantly of buprenorphine–naloxone (BNX). Both BPN and BNX are associated with diversion, abuse and non-medically supervised use worldwide. Our purpose was to estimate the proportion of BNX to all BPN-related fatalities. The material consisted of 225 deceased drug abusers in Finland from January 2010 to June 2011 with a positive BPN and/or norbuprenorphine (NOR) and/or naloxone (NX) finding in urine. The data were divided into three groups based on the urine NX and BPN concentrations. The “Parenteral BNX” group (>100μg/l NX) was presumed to consist of injecting or snorting BNX abusers and the “Parenteral BPN” group (>50μg/l BPN, 0μg/l NX) of injecting or snorting BPN abusers, whi…

Abstract: Buprenorphine (BPN) medication for opioid maintenance treatment in Finland consists predominantly of buprenorphine–naloxone (BNX). Both BPN and BNX are associated with diversion, abuse and non-medically supervised use worldwide. Our purpose was to estimate the proportion of BNX to all BPN-related fatalities. The material consisted of 225 deceased drug abusers in Finland from January 2010 to June 2011 with a positive BPN and/or norbuprenorphine (NOR) and/or naloxone (NX) finding in urine. The data were divided into three groups based on the urine NX and BPN concentrations. The “Parenteral BNX” group (>100μg/l NX) was presumed to consist of injecting or snorting BNX abusers and the “Parenteral BPN” group (>50μg/l BPN, 0μg/l NX) of injecting or snorting BPN abusers, whi…

ConclusionsFuture researchers may find utilization of the MI procedure in conjunction with the common method of GEE analysis as a helpful analytic approach when the missing at random assumption is justifiable. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

ConclusionsFuture researchers may find utilization of the MI procedure in conjunction with the common method of GEE analysis as a helpful analytic approach when the missing at random assumption is justifiable. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

ConclusionsFuture researchers may find utilization of the MI procedure in conjunction with the common method of GEE analysis as a helpful analytic approach when the missing at random assumption is justifiable. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

Conclusions: Unintentional exposure to buprenorphine can cause central nervous system depression, respiratory depression, and death in young children. Exposure rates to film formulations are significantly less than to tablet formulations. Package and storage deficiencies contribute to unintentional exposures in young children. (Source: The Journal of Pediatrics)

Abstract
CDC and NIDA Tout PrEP for HIV‐Negative Injecting Drug Users
Monitor Vendor Protocols when Signing up for Drug Testing
AAP OKs Breastfeeding on Methadone but Not Buprenorphine
ONDCP and SAMHSA Release Opioid Toolkit, Promote Naloxone
SAMHSA Releases Draft Outcome Measures, Gives 9/17 Deadline for Feedback
DOJ to Allow Marijuana Ballot Initiatives to Go Forward
Briefly Noted
In the States
Coming up (Source: Alcoholism and Drug Abuse Weekly)

Abstract
CDC and NIDA Tout PrEP for HIV‐Negative Injecting Drug Users
Monitor Vendor Protocols when Signing up for Drug Testing
AAP OKs Breastfeeding on Methadone but Not Buprenorphine
ONDCP and SAMHSA Release Opioid Toolkit, Promote Naloxone
SAMHSA Releases Draft Outcome Measures, Gives 9/17 Deadline for Feedback
DOJ to Allow Marijuana Ballot Initiatives to Go Forward
Briefly Noted
In the States
Coming up (Source: Alcoholism and Drug Abuse Weekly)